|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The synthesized nanoparticles were loaded with morusin, a naturally derived chemotherapeutic drug, and surface conjugated with CTX, a peptide derived from scorpion venom, highly specific for chloride channels (CIC-3) expressed in glioma tumor cells, as well as for matrix metalloproteinase (MMP-2), which is up regulated in the tumor microenvironment.
|
31423502 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tested tumors were positive for break-apart fluorescence in situ hybridization for CIC and NUTM1.
|
30407212 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The diagnosis was confirmed by fluorescent in situ hybridization after the tumor was found to be WT-1 positive, and comprehensive genomic profiling demonstrated breakpoints in exon 20 and exon 1 of the CIC and DUX4 genes, respectively.
|
28474974 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Some of these tumors harbor a specific CIC translocation.
|
30310990 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the new review all the tumors were re-classified as, ES (n=16), Ewing-like tumor with EWSR1 rearrangement and amplification and possible EWSR1-NFATC2 gene fusion (n=1), CIC-rearranged sarcomas or undifferentiated sarcoma, most consistent with CIC-rearranged sarcoma (n=7), sarcoma with BCOR-alteration or undifferentiated sarcoma, consistent with BCOR-associated sarcoma (n=3), neuroblastoma (n=2), unclassifiable neoplasm with neuroblastic differentiation (n=1), malignant rhabdoid tumor (n=2), lymphoblastic lymphoma (n=1), clear cell sarcoma of the gastrointestinal tract (n=1), small cell carcinoma (n=1), sclerosing rhabdomyosarcoma (n=1), desmoplastic small round cell tumor (n=1), malignant peripheral sheath nerve tumor (n=1), poorly-differentiated synovial sarcoma (n=1), Possible gastrointestinal stromal tumor/GIST with predominant round cells (n=1) and possible SMARCA4-deficient-sarcoma (n=1).
|
29661713 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To the best of our knowledge, this is the first study demonstrating the distinct prognostic value of altered CIC expression with regard to the 1p/19q status among <i>IDH</i>-mutant oligodendroglial tumors.
|
29434837 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, deletion of CIC caused a significant increase in tumor growth <i>in vivo</i> These results show that the RAS-MAPK pathway is involved in tumor progression and establish CIC as a powerful tumor suppressor that functions downstream of this pathway in neuroblastoma.<b>Significance:</b> This work identifies CIC as a powerful tumor suppressor affecting the RAS-MAPK pathway in neuroblastoma and reinforces the importance of mutation-driven activation of this pathway in cancer.<i></i>.
|
30115695 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These tumors were subjected to methylation profiling and could be assigned to Ewing sarcoma in 14 (47%), to small blue round cell tumors with CIC alteration in 6 (20%), to small blue round cell tumors with BCOR alteration in 4 (13%), to synovial sarcoma and to malignant rhabdoid tumor in 2 cases each.
|
29572501 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation.
|
29844126 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In light of morphologic features that overlap with those of NC from typical anatomical sites we have seen previously, the tumor was best classified as falling within the NC spectrum rather than CIC-associated sarcoma.
|
29700887 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Material from the needle biopsy was insufficient for CGP but that case was positive with the DUX4 immunohistochemical stain as were the 2 CIC-DUX4 tumors.
|
29901569 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study also refined the characteristics of some entities such as EWSR1-PATZ1 spindle cell sarcoma or FUS-NFATC2 bone tumours that are different from EWSR1-NFATC2 tumours and transcriptionally resemble CIC-fused tumour entities.
|
29431183 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CIC loss-of-function mutations are frequently observed in several human neoplasms such as oligodendroglioma, and lung and gastric carcinoma.
|
28985030 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, in our experience, DUX4 immunostaining distinguishes CIC-DUX4 tumors from other round cell mimics.
|
27879517 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The trunk alterations that existed throughout the course were restricted to IDH1 mutation, 1p/19q-codeletion, and TERT promoter mutation, and mutation of the known candidate tumor suppressor genes CIC and FUBP1 were not consistently observed between primary and recurrent tumors.
|
28270234 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This case report describes an additional case of <i>CIC-DUX4</i> sarcoma with a novel fusion breakpoint, and demonstrates the value of this next-generation sequencing-based anchored multiplex PCR technique (Archer FusionPlex Sarcoma Panel) in both diagnosis for patient care and in identification of a novel fusion breakpoint in this tumour type.
|
28137728 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene-expression profiles of CDS and eMC revealed upregulation of CIC-DUX4 downstream genes such as PEA3 family genes, <i>Ccnd2, Crh</i>, and <i>Zic1</i> IHC analyses for both mouse and human tumors showed that CCND2 and MUC5AC are reliable biomarkers to distinguish CDS from ES.
|
28404587 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We recognized the tumor as a genetically distinct variant of CIC-rearranged sarcomas with a novel NUTM2A-CIC fusion.
|
28188754 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As for small round cell sarcomas, novel fusion genes such as CIC-DUX4 and BCOR-CCNB3 have been identified in these tumor groups.
|
28759137 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results support the classification of CIC-rearranged tumors as an independent molecular and clinical subset of small blue round cell tumors distinct from Ewing sarcoma.
|
28346326 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After RT-PCR, the tumor sample was positive for the CIC-DUX4 fusion.
|
28062084 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All 3 CIC-rearranged AS cases lacked vasoformation and had a solid growth of round, epithelioid to rhabdoid cells, showing immunoreactivity for CD31 and Ets-related gene and sharing a transcriptional signature with other round cell sarcomas, including CIC-rearranged tumors.
|
26735859 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that the NM, CM and CD harboring sphere cells that were enriched with HN-CICs population exhibited impaired stemness and malignant properties in vitro, as well as reduced tumor growth ability in vivo.
|
27793047 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher expression of the oncogenic ETV transcription factors in the CIC-mutant oligodendrogliomas may make these tumors more aggressive than the CIC-wild type tumors.
|
26357005 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CIC gene is frequently mutated in oligodendroglial tumors with 1p19q codeletion.
|
26017892 |
2015 |